Transthoracic pulmonary artery radiofrequency denervation (TPARFD) concomitantly with cardiac operations in adult atrial septal defect with pulmonary arterial hypertension: case report

Wenpeng Dong; Shenglin Ge; Min Lin; Zhang Weida

doi:10.71321/89fykb91

Authors

Wenpeng Dong The First Affiliated Hospital of Anhui Medical University
Shenglin Ge The First Affiliated Hospital of Anhui Medical University
Min Lin The First Affiliated Hospital of Anhui Medical University
Zhang Weida General Hospital of Southern Theatre Command of PLA

DOI:

https://doi.org/10.71321/89fykb91

Keywords:

Pulmonary artery radiofrequency denervation, Pulmonary arterial hypertension, Congenital heart disease

Abstract

Pulmonary arterial hypertension (PAH) is a life-threatening progressive disorder caused by increased resistance in the pulmonary vasculature. The condition may lead to right-sided heart failure and death. A 56-year-old woman was referred for pulmonary arterial hypertension (PAH) with atrial septal defect, mitral regurgitation, and tricuspid regurgitation. Hemodynamic parameters were obtained by right heart catheterization. She underwent transthoracic pulmonary artery radiofrequency denervation (TPARFD), to relieve the pulmonary artery pressure, while concomitantly undergoing mitral valvuloplasty with 28 # Sorin ring, patch closure of atrial septal defect, and tricuspid annuloplasty with 28 # Edwards MC3 ring. Her hemodynamic parameters and functional capacity showed marked improvement after TPARFD.

References

1. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008;68:1049-66.

https://doi.org/10.2165/00003495-200868080-00004

2. van Dissel AC, Mulder BJ, Bouma BJ. The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. J Clin Med 2017;6:40.

https://doi.org/10.3390/jcm6050040

3. Boudjemline Y, Patel M, Malekzadeh-Milani S, Szezepanski I, Lévy M, Bonnet D. Patent ductus arteriosus stenting (transcatheter Potts shunt) for palliation of suprasystemic pulmonary arterial hypertension: a case series. Circ Cardiovasc Interv 2013;6:e18-20.

https://doi.org/10.1161/CIRCINTERVENTIONS.112.000072

4. Baruteau AE, Belli E, Boudjemline Y, Laux D, Lévy M, Simonneau G et al. Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. Eur J Cardiothorac Surg 2015;47:e105-10.

https://doi.org/10.1093/ejcts/ezu530

5. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study. J Am Coll Cardiol 2013;62:1092-1100.

https://doi.org/10.1016/j.jacc.2013.05.075

6. Chen SL, Zhang H, Xie DJ, Zhang J, Zhou L, Rothman AM et al. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes. Circ Cardiovasc Interv 2015;8:e002837.

https://doi.org/10.1161/CIRCINTERVENTIONS.115.002837

7. Zhang H, Zhang J, Chen M, Xie DJ, Kan J, Yu W et al. Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension. JACC Cardiovasc Interv 2019;12:274-84.

https://doi.org/10.1016/j.jcin.2018.09.032

8. Huang Y, Liu YW, Pan HZ, Zhang XL, Li J, Xiang L et al. Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol 2019;39:704-18.

https://doi.org/10.1161/ATVBAHA.118.312254